V
Vaxart
Vaccine technology for the treatment of infectious diseases
About Vaxart
Vaxart is a biotechnology company specializing in the development of oral recombinant vaccines. Operating in the rapidly growing $30 billion global vaccines market, Vaxart aims to unlock the full potential of oral vaccines, which are easier to administer and distribute compared to traditional injectable vaccines. The company's platform supports the rapid development, manufacture, and distribution of these vaccines, targeting diseases such as norovirus gastroenteritis and COVID-19. Vaxart primarily serves healthcare providers, governments, and organizations involved in public health. The business model focuses on research and development, clinical trials, and partnerships with larger pharmaceutical companies for commercialization. Revenue is generated through funding, grants, and potential licensing deals.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2004
- Headquarters
- South San Francisco, United States
- Listing
- IPO 2018
- Employees
- 109
- Open positions
- 2
- Dealroom signal
- 30.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
- Investment activity
- 1 company, latest Jun 2015
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Apr 2026 | $25M | — | Lincoln Park Capital | ↗ |
| POST IPO EQUITYOther financing | Jun 2024 | $40M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $201M | -15.5% | $28M | 14.1% |
| 2025 | $237M | +726.7% | $28M | 11.9% |
| 2024 | $29M | +288.9% | −$55M | -191.2% |
| 2023 | $7.4M | +6796.3% | −$72M | -977.5% |
| 2022 | $107K | -88% | −$106M | -99139.3% |
| 2021 | $892K | -78% | −$67M | -7482.3% |
| 2020 | $4M | — | −$32M | -787.6% |
Growth signals
Latest recorded traffic for Vaxart is 35K monthly website visits, up 366.7% over the last three months. Vaxart's team declined 4.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Life Science Angels- QPQuantum Technology Partners
Sand Hill Angels- BPBay Partners
- CCCare Capital
Series B and later2 investors entered at this stage
RA Capital Management
Lincoln Park Capital
Other known investors1 additional known investor
US Biomedical Advanced Research and Development Authority
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vaxart on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vaxart’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.